Heart transplantation and altered drug response, Part II: pharmacologic management of post-transplantation complications.
Boettger
Rebecca
R
Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, San Francisco, CA 94143-0622, USA.
Lee
Joyce
J
Rifkin
Celia
C
Kayser
Steven R
SR
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000209:etiology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002303:Cardiac Output, Low / Q000188:drug therapy / Q000209:etiology; D002316:Cardiotonic Agents / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D018579:Patient Selection; D011182:Postoperative Care / Q000379:methods / Q000451:nursing; D011183:Postoperative Complications / Q000188:drug therapy* / Q000209:etiology* / Q000451:nursing; D051437:Renal Insufficiency / Q000188:drug therapy / Q000209:etiology; D014665:Vasodilator Agents / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D014665:Vasodilator Agents